Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям

Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям

Автор: Елисеев М.С.

Журнал: Научно-практическая ревматология @journal-rsp

Рубрика: Международные и российские рекомендации по лечению ревматических заболеваний

Статья в выпуске: 6 т.55, 2017 года.

Бесплатный доступ

В 2016 г., по истечении 10 лет после публикации, впервые были обновлены международные рекомендации Европейской антиревматической лиги (EULAR) по лечению подагры. Заключительный вариант обновленных рекомендаций, включающий три базовых постулата и 11 позиций, оговаривающих принципы проведения симптоматической терапии острого приступа артрита и, что более важно, стратегии урат-снижающей терапии, направлен на возможность их практического использования; однако некоторые, не лишенные неоднозначных суждений, положения требуют обсуждения и пояснения, в том числе исходя из российских реалий.

Подагра, мочевая кислота, урат-снижающая терапия, аллопуринол, фебуксостат

Короткий адрес: https://sciup.org/14945869

IDR: 14945869   |   DOI: 10.14412/1995-4484-2017-600-609

Список литературы Обновленные рекомендации EULAR по лечению подагры. Комментарии к некоторым позициям

  • Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1): 29-42 DOI: 10.1136/annrheumdis-2016-209707
  • Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis. 2004; 63: 1172-6 DOI: 10.1136/ard.2004.023697
  • Van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015; 74: 8-13 DOI: 10.1136/annrheumdis-2014-206350
  • Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65: 1312-24 DOI: 10.1136/ard.2006.055269
  • Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012; 71: 1490-5 DOI: 10.1136/annrheumdis-2011-200801
  • Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011; 78: 456-9 DOI: 10.1016/j.jbspin.2011.05.010
  • Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013; 72: 826-30 DOI: 10.1136/annrheumdis-2012-201676
  • Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015; 67(4): 588-92 DOI: 10.1002/acr.22469
  • Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012; 64(10): 1431-46 DOI: 10.1002/acr.21772
  • Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol. 2011; 17: 349-5 DOI: 10.1097/RHU.0b013e3182314d40
  • Dalbeth N, Ames R, Gamble GD, et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis. 2012; 71 (6): 929-34 DOI: 10.1136/annrheumdis-2011-200156
  • Елисеев МС, Барскова ВГ. Диета при подагре. Доктор.Ру. 2011; (1): 55-8 .
  • Елисеев МС, Желябина ОВ. Влияние продуктов растительного происхождения на уровень мочевой кислоты: обзор литературы. Терапия. 2017; (4): 52-8
  • Holland R, McGill NW. Comprehensive dietary education in treated gout patients does not further improve serum urate. Intern Med J. 2015; 45(2): 189-94 DOI: 10.1111/imj.12661
  • Jalal DI, Chonchol M, Chen W, et al. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013; 61: 134-46 DOI: 10.1053/j.ajkd.2012.07.021
  • Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2011; 125: 679-87.e1 DOI: 10.1016/j.amjmed.2011.09.033
  • Кудаева ФМ, Гордеев АВ, Барскова ВГ. Скорость клубочковой фильтрации у больных подагрой и факторы, на нее влияющие. Современная ревматология. 2007; 1(1): 42-6
  • Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006; 54: 2688-96 DOI: 10.1002/art.22014
  • Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007; 116: 894-900 DOI: 10.1161/CIRCULATIONAHA.107.703389
  • De Vera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010; 69: 1162-4 DOI: 10.1136/ard.2009.122770
  • Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open. 2012; 2: e000282 DOI: 10.1136/bmjopen-2011-000282
  • Perez-Ruiz F, Martinez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014; 73: 177-82 DOI: 10.1136/annrheumdis-2012-202421
  • Liu SC, Xia L, Zhang J, et al. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS ONE. 2015; 10: e0134088 DOI: 10.1371/journal.pone.0134088
  • Clarson LE, Hider SL, Belcher J, et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015; 74: 642-7 DOI: 10.1136/annrheumdis-2014-205252
  • Елисеев МС, Денисов ИС, Маркелова ЕИ и др. Независимые факторы риска развития тяжелых сердечно-сосудистых осложнений у мужчин с подагрой: результаты 7-летнего проспективного исследования. Терапевтический архив. 2017; 89(5): 10-9
  • Haj Mouhamed D, Ezzaher A, Neffati F, et al. Effect of cigarette smoking on plasma uric acid concentrations. Environ Health Prevent Med. 2011; 16(5): 307-12 DOI: 10.1007/s12199-010-0198-2
  • Hanna BE, Hamed JM, Touhala LM. Serum uric acid in smokers. Oman Med J. 2008; 23(4): 269-74.
  • Gee Teng G, Pan A, Yuan JM, Koh WP. Cigarette smoking and risk of incident gout in the Singapore Chinese Health Study. Arthritis Care Res (Hoboken). 2016; 68(8): 1135-42 DOI: 10.1002/acr.22821
  • Wang W, Krishnan E. Cigarette smoking is associated with a reduction in the risk of incident gout: results from the Framingham Heart Study original cohort. Rheumatology (Oxford). 2015; 54(1): 91-5 DOI: 10.1093/rheumatology/keu304
  • Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009; 38: 411-9 DOI: 10.1016/j.semarthrit.2008.08.006
  • Saseen JJ. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. Rheumatology (Oxford). 2012; 51(11): 2004-12 DOI: 10.1093/rheumatology/kes183
  • Perez-Ruiz F, Castillo E, Chinchilla SP, Herrero-Beites AM. Clinical manifestations and diagnosis of gout. Rheum Dis Clin North Am. 2014 May; 40(2): 193-206 DOI: 10.1016/j.rdc.2014.01.003
  • Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010; 62: 1060-8 DOI: 10.1002/art.27327
  • Rainer TH, Cheng CH, Janssens HJ, et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, doubleblind, randomized trial. Ann Intern Med. 2016; 164: 464-71 DOI: 10.7326/M14-2070
  • Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. Lancet. 2008; 371: 1854-60 DOI: 10.1016/S0140-6736(08)60799-0
  • Man CY, Cheung IT, Cameron PA, et al. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute gout-like arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007; 49: 670-7 DOI: 10.1016/j.annemergmed.2006.11.014
  • Zhang YK, Yang H, Zhang JY, et al. Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout. Int J Clin Pract. 2014; 68(5): 633-8 DOI: 10.1111/ijcp.12359
  • Федорова АА, Барскова ВГ, Якунина ИА, Насонова ВА. Кратковременное применение применение глюкокортикоидов у больных затяжным и хроническим подагрическим артритом. Часть III -частота развития нежелательных реакций. Научнопрактическая ревматология. 2009; 47(2): 38-42
  • Richette P, Bardin T. Colchicine for the treatment of gout. Expert Opin Pharmacother. 2010; 11: 2933-8 DOI: 10.1517/14656566.2010.529432
  • Алекберова ЗС, Барскова ВГ. Колхицин в ревматолoгии -вчера и сегодня. Будет ли завтра? Современная ревматология. 2010; 4(2): 25-9
  • Sivera F, Wechalekar MD, Andres M, et al. Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev. 2014 Sep 1; (9): CD009993 DOI: 10.1002/14651858.CD009993.pub2
  • Bardin T, So A, Alten R, et al. Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal AntiInflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT. Arthritis Rheum. 2012; 64(10 Suppl): S811-2.
  • Елисеев МС, Желябина ОВ, Барскова ВГ, Насонов ЕЛ. Опыт применения ингибитора интерлейкина1р канакинумаба у больного с хронической тофусной подагрой. Научно-практическая ревматология. 2014; 52(1): 99-101
  • Елисеев МС, Желябина ОВ, Мукагова МВ, Насонов ЕЛ. Клинический опыт применения блокатора интерлейкина 1ß канакинумаба у больных хронической тофусной подагрой: купирование артрита и профилактика обострений при назначении аллопуринола. Современная ревматология. 2015; 9(2): 16-22
  • Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011 Jul; 70(7): 1264-71 DOI: 10.1136/ard.2010.144063
  • Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1ß inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebocontrolled trial. Circulation. 2012; 126(23): 2739-48 DOI: 10.1161/CIRCULATI0NAHA.112.122556
  • Елисеев МС, Желябина ОВ, Маркелова ЕИ др. Оценка кардиоваскулярного риска при применении ингибитора интерлейкина 1 у больных тяжелой тофусной подагрой. Современная ревматология. 2016; 10(1): 7-14
  • Елисеева МЕ, Цурко ВВ, Воробьев ПА. Пожилой пациент с подагрой, лечение у терапевта. Клиническая геронтология. 2015; 21(5-6): 3-9
  • Becker MA, MacDonald PA, Hunt BJ, et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008; 27: 585-91 DOI: 10.1080/15257770802136032
  • Wortmann RL, Macdonald PA, Hunt B, et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase IIItrials. Clin Ther. 2010; 32: 2386-97 DOI: 10.1016/j.clinthera.2011.01.008
  • Crittenden DB, Kimmel JN, Pike VC, et al. Colchicine and risk of acute cardiovascular (CV) events among gout patients: the New York Department of veterans affairs retrospective cohort study. Arthritis Rheum. 2014; 66(11 Suppl.): S65.
  • Solomon DH, Liu CC, Kuo IH, et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016; 75(9): 1674-9 DOI: 10.1136/annrheumdis-2015-207984
  • Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013; 61: 1679-85 DOI: 10.1016/j.jacc.2013.01.055
  • Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low dose colchicine for secondary prevention of cardiovascular disease. JACC. 2013; 61: 404-10 DOI: 10.1016/j.jacc.2012.10.027
  • Yu J, Qiu Q, Liang L, et al. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 2017 May 9 DOI: 10.1080/14397595.2017.1318467
  • Schumacher HR Jr, Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012; 64: 876-84 DOI: 10.1002/art.33412
  • Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford). 2013; 52: 1285-92 DOI: 10.1093/rheumatology/ket114
  • Schumacher HR Jr, Evans RR, Saag KG, et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken). 2012; 64: 1462-70 DOI: 10.1002/acr.21690
  • Sundy JS, Schumacher HR, Kivitz A, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. JRheumatol. 2014; 41: 1703-11 DOI: 10.3899/jrheum.131226
  • Елисеев МС. Подагра. В кн.: Ревматология. Клинические российские рекомендации. Москва: ГЭОТАР-Медиа; 2017. С. 253-64
  • Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015; 11(11): 649-62 DOI: 10.1038/nrrheum.2015.91
  • Насонова ВА, Елисеев МС, Барскова ВГ. Влияние возраста на частоту и выраженность признаков метаболического синдрома у больных подагрой. Современная ревматология. 2007; 1(1): 31-6
  • Барскова ВГ, Елисеев МС, Зилов АВ, Насонов ЕЛ. Влияние гипергликемии и гиперинсулинемии на уровень мочевой кислоты и течение артрита у больных подагрой с сахарным диабетом 2 типа. Ожирение и метаболизм. 2007; (1): 19-23
  • Pillinger MH, Bangalore S, Klein AB, et al. Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization. J Manag Care Spec Pharm. 2017; 23(6): 677-83 DOI: 10.18553/jmcp.2017.23.6.677
  • Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol. 2011; 23(2): 156-60 DOI: 10.1097/B0R.0b013e3283432d35
  • Becker MA, Schumacher H Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353: 2450-61 DOI: 10.1056/NEJMoa050373
  • Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59: 1540-8 DOI: 10.1002/art.24209
  • Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology. 2009; 48: 188-94 DOI: 10.1093/rheumatology/ken457
  • Strand V, Khanna D, Singh JA, et al. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol. 2012; 39: 1450-7 DOI: 10.3899/jrheum.111375
  • Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS ONE. 2012; 7: e50046 DOI: 10.1371/journal.pone.0050046
  • Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk. Clin J Am Soc Nephrol. 2010; 5(8): 1388-93 DOI: 10.2215/CJN.01580210
  • Sezer S, Karakan S, Atesagaoglu B, Acar FN. Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia. Saudi J Kidney Dis Transpl. 2014; 25(2): 316-20 DOI: 10.4103/13192442.128520
  • Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012; 30: 217-26 DOI: 10.1111/j.1755-5922.2011.00277.x
  • Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013; 15: 435 42 DOI: 10.1111/j.1751-7176.2012.00701.x
  • Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and metaanalysis. Nephrol Dial Transplant. 2014; 29: 406-13 DOI: 10.1093/ndt/gft378
  • Kanji T, Gandhi M, Clase CM, et al. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015; 16: 58 DOI: 10.1186/s12882-015-0047-z
  • Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and allcause mortality in the general population. Ann Rheum Dis. 2015 Jul; 74(7): 1368-72 DOI: 10.1136/annrheumdis-2014-205269
  • Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010; 375(9732): 2161-7 DOI: 10.1016/S0140-6736(10)60391-1
  • Wei L, Fahey T, Struthers AD, MacDonald TM. Association between allopurinol and mortality in heart failure patients: a longterm follow-up study. Int J Clin Prac. 2009; 63(9): 1327-33 DOI: 10.1111/j.1742-1241.2009.02118.x
  • Gaffo AL, Dalbeth N, Saag KG, et al. Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study . Arthritis Rheum. 2016; 68 Suppl 10.
  • Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine. 2015; 82: 141-3 DOI: 10.1016/j.jbspin.2015.01.002
  • Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007; 57: 1324-8 DOI: 10.1002/art.23007
  • Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002; 47: 356-60 DOI: 10.1002/art.10511
  • Елисеев МС, Мукагова МВ, Смирнов АН и др. Атипичная подагра: тофусное поражение позвоночника. Научно-практическая ревматология. 2013; 51(5): 586-9
  • Барскова ВГ, Елисеев МС. Больная хронической подагрой: комментарии к течению болезни. Современная ревматология. 2010; 4(1): 32-8
  • Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2007; 46: 1372-4 DOI: 10.1093/rheumatology/kem056a
  • Mironczuk-Chodakowska I, Witkowska AM, Zujko ME. Endogenous non-enzymatic antioxidants in the human body. Adv MedSci. 2017; 63(1): 68-78 DOI: 10.1016/j.advms.2017.05.005
  • Chamorro A, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol. 2014; 13: 453-60 DOI: 10.1016/S1474-4422(14)70054-7
  • Schretlen DJ, Inscore AB, Vannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007; 69: 1418-23 DOI: 10.1212/01.wnl.0000277468.10236.f1
  • Kim TS, Pae CU, Yoon SJ, et al. Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2006; 21: 344-8 DOI: 10.1002/gps.1469
  • Du N, Xu D, Hou X, et al. Inverse Association Between Serum Uric Acid Levels and Alzheimer's Disease Risk. Mol Neurobiol. 2016; 53(4): 2594-9 DOI: 10.1007/s12035-015-9271-6
  • Chen H, Mosley TH, Alonso A, et al. Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009; 169: 1064-9 DOI: 10.1093/aje/kwp033
  • Weisskopf MG, O'Reilly E, Chen H, et al. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007; 166: 561-7 DOI: 10.1093/aje/kwm127
  • Wen M, Zhou B, Chen YH, et al. Serum uric acid levels in patients with Parkinson's disease: A meta-analysis. PLoS One. 2017; 12(3): e0173731 DOI: 10.1371/journal.pone.0173731
  • Abraham A, Drory VE. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 2014; 261: 1133-8 DOI: 10.1007/s00415-014-7331-x
  • Lu N, Dubreuil M, Zhang Y, et al. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016 Mar; 75(3): 547-51 DOI: 10.1136/annrheumdis-2014-206917
  • Chen X, Guo X, Huang R, et al. Serum uric acid levels in patients with Alzheimer's disease: a meta-analysis. PLoS One. 2014; 9(4): e94084. eCollection 2014 DOI: 10.1371/journal.pone.0094084
  • Verhaaren BF, Vernooij MW, Dehghan A, et al. The relation of uric acid to brain atrophy and cognition: the Rotterdam Scan Study. Neuroepidemiology. 2013; 41(1): 29-34 DOI: 10.1159/000346606
  • Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009; 11: R46 DOI: 10.1186/ar2659
  • Solomon DH, Avorn J, Levin R, et al. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008; 67: 609-13 DOI: 10.1136/ard.2007.076182
  • Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: the «dirty dish» hypothesis. Arthritis Rheum. 2011; 63: 4002-6 DOI: 10.1002/art.30649
  • Chowalloor PV, Keen HI. A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Ann Rheum Dis. 2013; 72(5): 638-45 DOI: 10.1136/annrheumdis-2012-202301
  • Eliseev M, Zhelyabina O, Vladimirov S, et al. Ultrasonography signs of MSU urate deposition in patients with hyperuricemia and early diagnosis of gout. Ann Rheum Dis. 2016; 75 Suppl 2: 1183 DOI: 10.1136/annrheumdis-2016-eular.4166
  • Reinders MK, Haagsma C, Jansen T, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009; 68: 892-7 DOI: 10.1136/ard.2008.091462
  • Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009; 68: 51-6 DOI: 10.1136/ard.2007.083071
  • Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12: R63 DOI: 10.1186/ar2978
  • Li S, Yang H, Guo Y, et al. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Scientific Reports. 2016; 6: Article number 33082 DOI: 10.1038/srep33082
  • Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012; 64: 2529-36 DOI: 10.1002/art.34488
  • Jutkowitz E, Alarid-Escudero F, Choi HK, et al. Cost-Effectiveness of Allopurinol and Febuxostat for the Management of Gout. Ann Intern Med. 2014; 16: 617-26 DOI: 10.7326/M14-0227
  • Ryu H, Song R, Kim H, et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol. 2013; 53: 211-6 DOI: 10.1177/0091270012439715
  • Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheum. 2016; 12: 235-42 DOI: 10.1038/nrrheum.2015.132
  • Ramasamy SN, Korb-Wells CS, Kannangara DR, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf. 2013; 36: 953-80 DOI: 10.1007/s40264-013-0084-0
  • Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2015; 74: 2157-64 DOI: 10.1136/annrheumdis-2014-205577
  • Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009; 11: 135-40 DOI: 10.1007/s11926-009-0019-z
  • Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017; 76(9): 1522-8 DOI: 10.1136/annrheumdis-2016-210872
  • Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011; 63(2): 412-21 DOI: 10.1002/art.30119
  • Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006; 33: 1646-50.
  • Hira D, Chisaki Y, Noda S, et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology. 2015; 96: 90-8 DOI: 10.1159/000434633
  • Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008; 58: 2882-91 DOI: 10.1002/art.23810
  • Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014; 16: R60 DOI: 10.1186/ar4497
  • Елисеев МС, Барскова ВГ, Якунина ИА. Диагноз подагра -противопоказние к назначению диуретиков. Фарматека. 2003; (5): 67-70
  • Ranieri L, Contero C, Andres M. Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort. Ann Rheum Dis. 2017; 6 Suppl 2: 372 DOI: 10.1136/annrheumdis-2017-eular.3905
  • Choi HK, Soriano LC, Zhang Y, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012; 344: d8190 DOI: 10.1136/bmj.d8190
  • Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and metaanalysis of randomized placebo-controlled trials. Pharmacol Res. 2015; 102: 63-70 DOI: 10.1016/j.phrs.2015.09.012
  • Ansquer JC, Dalton RN, Causse E, et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008; 51: 904-13 DOI: 10.1053/j.ajkd.2008.01.014
  • Ogata N, Fujimori S, Oka Y, et al. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids. 2010; 29: 321-4 DOI: 10.1080/15257771003741323
  • Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol. 2012; 157: 255-7 DOI: 10.1016/j.ijcard.2012.01.092
  • Елисеев МС, Барскова ВГ, Денисов ИС. Динамика клинических проявлений подагры у мужчин (данные 7-летнего ретроспективного наблюдения). Терапевтический архив. 2015; 87(5): 10-5
Еще
Статья научная
SciUp 2024 © 2024 ©